May 2026 GLP-1 Market Report: Who's Still Standing After the FDA Crackdown

14 months after the FDA's September 2025 enforcement wave, the compounded GLP-1 telehealth market looks fundamentally different. Here's the data on what survived, what didn't, and what the current landscape means for patients.

In September 2025, the FDA issued warning letters to more than 50 GLP-1 telehealth companies in a single enforcement action — the largest coordinated crackdown in the compounding industry's history. The letters cited misleading claims: providers describing compounded products as "FDA-approved," using Novo Nordisk and Eli Lilly brand names for compounded formulations, and making unsubstantiated efficacy claims.

Simultaneously, the semaglutide shortage ended (February 2025) and the tirzepatide shortage ended (December 2024), removing the regulatory basis that had allowed compounding pharmacies to produce copies of these drugs at scale. Eli Lilly launched aggressive trademark litigation — 130+ lawsuits against compounders and telehealth platforms. The market was supposed to contract dramatically.

It did contract. But it didn't collapse. Here's what actually happened.

The Numbers: Market Contraction

IQVIA's October 2025 report found that despite the shortage resolution, compounded GLP-1 prescriptions continued to rise — suggesting that patient demand persists even as regulatory pressure increases. The providers that exited were disproportionately the smaller, less-compliant operators. Larger companies with legal counsel and compliant formulations have generally survived.

What Killed Providers

1. FDA Warning Letters With No Path to Compliance

Providers who had marketed compounded semaglutide as "the same as Ozempic" or "FDA-approved" had no easy fix. The warning letters required them to fundamentally restructure their marketing — and many found that their customer acquisition model depended on exactly the claims the FDA prohibited.

2. Eli Lilly Trademark Litigation

Lilly's legal team has been relentless. Telehealth companies using "Mounjaro," "Zepbound," or similar branding in advertising faced lawsuits they couldn't afford to fight. Several settled by agreeing to stop selling compounded tirzepatide entirely.

3. The Shortage Basis Disappeared

Providers who had been compounding exact copies of branded formulations under the shortage exemption lost their legal basis. Those who didn't pivot to "clinically significant difference" formulations (adding B12, NAD+, alternative delivery methods) had to stop production.

4. Brand-Name Pricing Compression

LillyDirect at $399/month and NovoCare at $349–$499/month squeezed the high end of the compounded market. Providers charging $350+ for compounded products suddenly couldn't justify the price when FDA-approved alternatives were within $50–$100.

What Survivors Have in Common

Current Market Pricing: May 2026

The pricing compression is the most significant market shift of the past year. In early 2025, the cheapest compounded option was roughly $180/month and brand-name was $1,000+. The gap was ~$800. Today, the gap between budget compounded ($146) and self-pay brand-name ($349) is ~$200 — and at the premium compounded tier ($300–$350), it's essentially parity with brand-name self-pay pricing.

New Entrants Worth Watching

While many providers exited, new entrants have arrived — generally with more sophisticated compliance strategies from day one.

Bodybuilding.com GLP-1 & Longevity entered through the Katalys affiliate network with a $400 CPA — the highest in the market. Their positioning targets fitness-oriented users, which is a differentiated approach in a market dominated by weight-loss framing. Katalys Program 1585

Oak Weight Loss launched across all major affiliate sources at $350 CPA, positioning as a structured clinical program rather than a medication delivery service. Katalys Program ID TBD

Gala GLP-1 entered with a $179/month flat pricing model — no dose escalation surcharges. At $320 CPA, their economics favor high-volume conversion from price-conscious patients. Katalys Program 1576

What This Means for Patients

The post-crackdown market is objectively better for patients than the pre-crackdown market. The providers remaining tend to be more transparent, more compliant, and more competitively priced. Brand-name alternatives are more accessible than ever. The trade-off is fewer choices — but the choices removed were disproportionately the ones most likely to cause problems.

The key decisions for patients haven't changed: verify pharmacy credentials (503A vs 503B), check for FDA warning letters, understand your formulation, and compare total cost-of-ownership (not just monthly sticker price).

Providers With Clean Regulatory Records